Complete cytogenetic but not molecular remission in a patient with myeloid blast crisis of chronic myeloid leukemia treated with carboplatin and ara-C.
We report on a patient diagnosed with myeloid BC-CML in which a complete cytogenetic remission confirmed by FISH assay was obtained after therapy with carboplatin-ARA-C. However, RT-PCR analysis showed persistence of the p210 bcrabl translocation. Accordingly, the level of residual malignant cells should be between 10(-2) and 10(-6). Autologous stem cell transplantation was performed, but relapse occurred 11 months after blast crisis. This case supports the effectiveness of a carboplatin-ARA-C protocol in BC-CML in order to induce cytogenetic remissions.
Pérez-Simón
J A
JA
Servicio de Hematología, Hospital Clinico Universitario de Salamanca, Spain.
Caballero
M D
MD
Hernandez-Rivas
J M
JM
Chillón
C
C
García-Isidoro
M
M
San Miguel
J F
JF
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D016190:Carboplatin